Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
UBS
Teva
Baxter
Federal Trade Commission

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 6,682,734

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,682,734
Title: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Abstract:Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Inventor(s): Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Olivenhain, CA), Leonard; John E. (Encinitas, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Sante Fe, CA)
Assignee: IDEC Pharmaceuticals Corporation (San Diego, CA)
Application Number:08/475,813
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,682,734
Patent Claims:see list of patent claims

Details for Patent 6,682,734

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Sign Up IDEC Pharmaceuticals Corporation (San Diego, CA) 2021-01-27 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Baxter
AstraZeneca
Harvard Business School
Mallinckrodt
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.